Biopharma Co. Escapes Investor Suit Over Drug Approval Lies

Biopharmaceutical company Spero Therapeutics Inc. has escaped a proposed investor class action accusing it of concealing warning signs that it would not secure regulatory approval of one of its drugs, with...

Already a subscriber? Click here to view full article